[D-p-Cl-Phe6,Leu17]-VIP acetate

TargetMol
Product Code: TAR-TP2103L
Supplier: TargetMol
CodeSizePrice
TAR-TP2103L-1mg1mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2103L-5mg5mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2103L-10mg10mg£759.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2103L-25mg25mg£1,310.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2103L-50mg50mg£1,929.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Further Information

Bioactivity:
[D-p-Cl-Phe6,Leu17]-VIP acetate is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor (IC50 = 125.8 nM).
CAS:
0
Formula:
C150H243ClN44O44
Molecular Weight:
3402.26
Purity:
0.98
SMILES:
[H]N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC(N)=O)=O)CC(C)C)=O)[C@H](CC)C)=O)CO)=O)CC(N)=O)=O)CC(C)C)=O)CC1=CC=C(C=C1)O)=O)CCCCN)=O)CCCCN)=O)C(C)C)=O)C)=O)CC(C)C)=O)CCC(N)=O)=O)CCCCN)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCNC(N)=N)=O)[C@H](O)C)=O)CC2=CC=C(C=C2)O)=O)CC(N)=O)=O)CC(O)=O)=O)[C@H](O)C)=O)CC3=CC=C(C=C3)Cl)=O)C(C)C)=O)C)=O)CC(O)=O)=O)CO)=O)CC4=CNC=N4.CC(O)=O

References

Pozo D, et, al. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. Eur J Pharmacol. 1997 Mar 5; 321(3): 379-86. Pandol SJ, et, al. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol. 1986 Apr; 250 (4 Pt 1): G553-7. Messmer B, et, al. Regulation of exocrine pancreatic secretion by cerebral TRH and CGRP: role of VIP, muscarinic, and adrenergic pathways. Am J Physiol. 1993 Feb; 264(2 Pt 1): G237-42.